These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 36052821)
1. A population pharmacokinetic-pharmacodynamic model of navtemadlin, its glucuronide metabolite (M1) and serum macrophage inhibitory cykokine-1 (MIC-1). Zhang L; Poland B; Green M; Wong S; Slatter JG Xenobiotica; 2022 Jun; 52(6):555-566. PubMed ID: 36052821 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Macrophage Inhibitory Cytokine-1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT-232) in Fed and Fasted Healthy Subjects. Wong S; Krejsa C; Lee D; Harris A; Simard E; Wang X; Allard M; Podoll T; O'Reilly T; Slatter JG Clin Pharmacol Drug Dev; 2022 May; 11(5):640-653. PubMed ID: 35172043 [TBL] [Abstract][Full Text] [Related]
3. BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis. Verstovsek S; Al-Ali HK; Mascarenhas J; Perkins A; Vannucchi AM; Mohan SR; Scott BL; Woszczyk D; Koschmieder S; García-Delgado R; László R; McGreivy JS; Rothbaum WP; Kiladjian JJ Future Oncol; 2022 Nov; ():. PubMed ID: 36416118 [TBL] [Abstract][Full Text] [Related]
4. The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK Cancer Res Commun; 2022 Sep; 2(9):1075-1088. PubMed ID: 36922937 [TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. Zhang J; Xu JF; Liu YB; Xiao ZK; Huang JA; Si B; Sun SH; Xia QM; Wu XJ; Cao GY; Shi YG; Zhang YY J Infect Chemother; 2009 Oct; 15(5):293-300. PubMed ID: 19856067 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections. Wang T; Xie J; Wang Y; Zheng X; Lei J; Wang X; Dong H; Yang Q; Chen L; Xing J; Dong Y Pharmacotherapy; 2015 Sep; 35(9):797-804. PubMed ID: 26406771 [TBL] [Abstract][Full Text] [Related]
7. New concept and a theoretical consideration of the mechanism-based pharmacokinetics/ pharmacodynamics (PK/PD) modeling for antimicrobial agents. Sato N; Suzuki H; Hayashi H; Shibasaki S; Sugano T; Maebashi K; Kurosawa T; Shiomi M; Ogata H Jpn J Antibiot; 2008 Oct; 61(5):314-38. PubMed ID: 19260351 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic evaluation of marbofloxacin after intravenous administration at different ages in llama crias, and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation. Rubio-Langre S; Aguilar-Sola S; Lorenzutti AM; San Andrés MI; De Lucas JJ; Litterio NJ J Vet Pharmacol Ther; 2018 Dec; 41(6):861-870. PubMed ID: 30020535 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models. Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075 [TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Staatz CE; Tett SE Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457 [TBL] [Abstract][Full Text] [Related]
11. Population-Based Pharmacokinetics and Dose Optimization of Imipenem in Vietnamese Critically-Ill Patients. Dinh TD; Nguyen HN; Le BH; Nguyen TTT; Nguyen HTL Infect Drug Resist; 2022; 15():4575-4583. PubMed ID: 36003989 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580 [TBL] [Abstract][Full Text] [Related]
13. Dose findings of antofloxacin hydrochloride for treating bacterial infections in an early clinical trial using PK-PD parameters in healthy volunteers. Li YF; Wang K; Yin F; He YC; Huang JH; Zheng QS Acta Pharmacol Sin; 2012 Nov; 33(11):1424-30. PubMed ID: 22864303 [TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. Dong M; Fukuda T; Cox S; de Vries MT; Hooper DK; Goebel J; Vinks AA Br J Clin Pharmacol; 2014 Nov; 78(5):1102-12. PubMed ID: 24837828 [TBL] [Abstract][Full Text] [Related]
15. A proposal of a pharmacokinetic/pharmacodynamic (PK/PD) index map for selecting an optimal PK/PD index from conventional indices (AUC/MIC, Cmax/MIC, and TAM) for antibiotics. Kitamura Y; Yoshida K; Kusama M; Sugiyama Y Drug Metab Pharmacokinet; 2014; 29(6):455-62. PubMed ID: 25008846 [TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680 [TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics and Pharmacodynamics Modelling of Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome. Yang S; Dumitrescu TP Drugs R D; 2017 Mar; 17(1):145-158. PubMed ID: 28004376 [TBL] [Abstract][Full Text] [Related]